Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001

Cambridge, UK - 19th October 2017

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has signed an agreement with Quotient Clinical (‘Quotient’), a leading provider of specialist drug development services, to conduct a pilot bioequivalence study for one of Nuformix’ lead programmes, NXP001, based on a currently marketed treatment in the field of oncology supportive care.

Click here to view the full article